TABLE 2.
Medical treatment and maternal outcomes among pregnant women admitted due to COVID‐19 from March to August 2020 by country.
| BOSS | ItOSS | NethOSS | NOSS | UKOSS | |
|---|---|---|---|---|---|
| National, Belgium | National, Italy | National, the Netherlands | National, Denmark, Finland & Norway | National, United Kingdom | |
| Total women admitted due to COVID‐19, n | 33 | 153 | 45 | 24 | 656 |
| Medical treatment, n (%) | |||||
| Antibiotics (alone) | 16 (48.5) | 11 (7.2) | 20 (44.4) | 9 (40.9) | 174 (26.5) |
| Antivirals (alone) | 1 (3.0) | 4 (2.6) | 0 | 0 | 7 (1.1) |
| Antibiotic and antiviral in combination | 0 | 9 (5.9) | 2 (4.4) | 4 (18.2) | 8 (1.2) |
| Hydroxychloroquine | 15 (45.5) | 88 (57.9) | 5 (11.1) | 0 | 0 |
| Anti‐Interleukin 6 | 0 | NA | 0 | 0 | 0 |
| I.v. Immunoglobulins | 0 | NA | NA | 0 | 0 |
| Steroids for fetal indication | 3 (9.1) | 21 (13.8) | 6 (13.3) | 6 (27.3) | 105 (16.0) |
| Steroids for maternal indication | 3 (9.1) | NA | 0 | 2 (9.1) b | 7 (1.1) |
| Thrombosis prophylaxis | 12 (36.4) | 55 (36.2) | NA | 12 (54.5) | 89 (13.6) |
| Anti‐thrombotic treatment | 1 (3.0) | NA | NA | 1 (4.5) | 1 (0.2) |
| ICU admission, n (%) | 3 (9.1) | 15 (9.8) | 4 (8.9) | 4 (17.4) | 53 (8.1) |
| Maximum level of respiratory support, n (%) a | |||||
| Mechanical ventilation or ECMO | 4 (12.1) | 7 (4.6) | 3 (6.7) | 3 (13.0) | 25 (13.2) |
| CPAP or high flow nasal cannula | NA | 19 (12.4) | NA | 0 | 15 (7.9) |
| Oxygen supplementation | NA | 44 (28.8) | 22 (48.9) | 6 (28.6) | 17 (8.9) |
| Maternal death, n (%) | 0 | 0 | 0 | 0 | 7 (1.1) |
Abbreviations: COVID‐19, coronavirus disease 2019; CPAP, continuous positive airway pressure; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; I.v., intravenous; NA, not available.
a
In UKOSS, maximum level of respiratory support was measured only among women who received respiratory support (n = 190); level of respiratory support was unknown for 57/190 women.
b
Includes one with known non‐COVID‐19 indication.